Carcinoma, Non-Small-Cell Lung Clinical Trials in New Brunswick, New Jersey

3 studies are recruiting for carcinoma, non-small-cell lung in New Brunswick, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

    The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characteriz…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
    Locations
    110 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT05498428 on ClinicalTrials.gov

  2. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
    Locations
    203 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT06667076 on ClinicalTrials.gov

  3. A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

    The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is comp…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
    Locations
    43 in total
    Run by
    Johnson & Johnson Enterprise Innovation Inc.

    See if you can join NCT06667908 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.